Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
Status:
Recruiting
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
This trial aims to evaluate whether the addition of anti-PD-1 antibody to adjuvant
postoperative chemoradiotherapy could improve disease free survival in patients with
high-risk locally advanced head and neck squamous cell carcinoma (HNSCC).
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences